Recent Activity

Loading...

BIO

Bio-Rad Laboratories, Inc. Class A · NYSE

Performance

-0.55%

1W

-17.35%

1M

-17.5%

3M

-11.41%

6M

-16.92%

YTD

-29.1%

1Y

Profile

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Investment Analysis Report: BioTech Inc. (BIO)

Overview:

BioTech Inc. (BIO) operates in the Health Technology sector, specifically in Medical Specialties. The company has a market capitalization of $7.92 billion. In this report, we will conduct a comprehensive analysis of BIO's financial statements to evaluate its investment potential.

Balance S...

See more ...

Technical Analysis of BIO 2024-05-03

Overview:

In analyzing the technical indicators for the last 5 days of BIO stock, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for potential ...

See more ...

Recent News & Updates